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 
Abstract—The successful development of amyloid-based 
biomarkers and tests for Alzheimer’s disease (AD) represents an 
important milestone in AD diagnosis. However, two major 
limitations remain. Amyloid-based diagnostic biomarkers and 
tests provide limited information about the disease process and 
they are unable to identify individuals with the disease before 
significant amyloid-beta accumulation in the brain develops. The 
objective in this study is to develop a method to identify potential 
blood-based non-amyloid biomarkers for early AD detection. The 
use of blood is attractive because it is accessible and relatively 
inexpensive. Our method is mainly based on machine learning 
(ML) techniques (support vector machines in particular) because 
of their ability to create multivariable models by learning patterns 
from complex data.  Using novel feature selection and evaluation 
modalities we identified 5 novel panels of non-amyloid proteins 
with the potential to serve as biomarkers of early AD. In 
particular, we found that the combination of A2M, ApoE, BNP, 
Eot3, RAGE and SGOT may be a key biomarker profile of early 
disease.  Disease detection models  based on the identified panels 
achieved sensitivity (SN) > 80%, specificity (SP) > 70%, and area 
under receiver operating curve (AUC) of at least 0.80 at 
prodromal stage (with higher performance at later stages) of the 
disease. Existing ML models performed poorly in comparison at 
this stage of the disease suggesting that the underlying protein 
panels may not be suitable for early disease detection. Our results 
demonstrate the feasibility of early detection of AD using non-
amyloid based biomarkers. 
 
Index Terms—Alzheimer’s disease, blood biomarker, dementia, 
machine learning, support vector machine. 
I. INTRODUCTION 
LZHEIMER’S disease (AD) is the leading cause of 
dementia and poses a significant social and economic 
challenge. It  is  responsible  for more  than  half of all cases of  
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dementia [1]. Over 50 million individuals currently suffer from 
dementia worldwide with a projected increase to 152 million by 
2050 [2].  
No cure for AD has been discovered, but there is intense 
effort to develop new clinical interventions that may slow or 
halt the disease. Such interventions are aimed at early 
(including preclinical and prodromal [3]) stages of the disease 
prior to extensive cell damage, when it is thought treatment is 
more likely to be effective.  
To facilitate early diagnosis [4-6], the use of established 
biomarkers such as those based on amyloid-beta in cerebral 
spinal fluid (CSF) and molecular imaging of brain amyloid 
deposition using positron emission tomography (PET) is 
recommended [4-6]. 
However, despite progress with the development of amyloid-
based biomarkers and tests for early AD diagnosis, they have 
two major constraints [7-9]. Amyloid-based biomarkers 
provide limited information about disease pathological 
aetiology and pathways [10-12]. In addition, tests based on 
these biomarkers are unable to identify individuals at risk of AD   
prior to a significant amyloid-beta deposition in the brain. 
There is a need for biomarkers that have the potential to 
detect biological processes that precede brain amyloid-beta 
accumulation (amyloid pathology) during the disease 
development. Such biomarkers may advance understanding of 
the disease, aid identification of individuals at the early disease 
stages and the development of new interventions. 
Studies suggest that AD is characterised by metabolic 
alterations [4] that may precede amyloid pathology [12]. 
Signatures of such metabolic abnormalities may therefore serve 
as biomarkers of earlier stages of the disease than amyloid 
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biomarkers.  Such biomarkers may be obtained from blood 
since blood has rich metabolic information content. The use of 
blood is also attractive because blood biomarker-based test is 
relatively non-invasive compared to CSF and may be more 
cost-effective than PET imaging. A number of studies have 
attempted to find non-amyloid biomarkers of disease by 
profiling a large array of non-amyloid proteins in blood and 
examining their association with the disease [13-15], but this 
approach is difficult to apply in practice.  
A promising approach is the use of machine learning (ML) 
techniques to find appropriate combinations of   non-amyloid 
proteins to detect AD as no single non-amyloid protein has been 
shown to reliably detect the disease. ML makes it possible to fit 
multivariable data to a model by learning complex patterns 
from data. Several studies [16-24] have applied ML to develop 
classifiers to differentiate between AD subjects and healthy 
controls. For example, O’Bryant et al. [19] developed a model 
with a panel of 30 serum proteins that classified Alzheimer’s 
disease dementia (ADD) subjects and HCs with sensitivity 
(SN), specificity (SP), and area under receiver operating curve 
(AUC) of 88%, 82%, and 0.91, respectively. Similarly, with 14 
plasma proteins, a classifier model constructed by Llano et al. 
[22] classified ADD and HC subjects with 86.5% SN, 84.2% 
SP and AUC of 0.85. More recently, a panel of inflammatory 
markers in plasma was identified that classified ADD and HC 
with 84% SN, 70% SP, and AUC of 0.79 using a logistic 
regression model [25]. In another study, a 12-marker panel 
classified ADD and HC with 90% SN and 66.7% specificity, 
and higher performance in post-mortem confirmed AD cases 
[26]. Furthermore, a study [27] that explored the use of deep 
learning, random forest, and XGBoost algorithms for 
classification of ADD and HC achieved AUC of 0.88 with 
XGBoost algorithm and 0.85 with deep learning and random 
forest. Despite the promising results from these studies, most of 
the models were developed and evaluated using data from 
cognitively healthy controls and subjects at the later stages of 
the disease. The models were not evaluated in individuals at the 
early stages of the disease. Therefore, the panels underlying 
such models may not be suitable as biomarker signatures of 
early AD.   
In this study, the main objective is to develop a ML-based 
method (support vector machines (SVM) in particular – see 
later) to identify blood biomarkers of early AD based on non-
amyloid proteins with the potential to identify the disease prior 
to accumulation of amyloid-beta in the brains. 
 We also assess the potential of existing ML-based methods 
to achieve early disease detection. 
The rest of this paper is structured as follows. The materials 
and methods are described in Sections II and III. The results are 
presented in Section IV, and the discussion and conclusions are 
provided in Sections V and VI.  
II. MATERIALS  
A. Blood proteomic data 
Blood proteomic data used in this study were obtained from the 
Alzheimer’s  disease  neuroimaging   initiative  (ADNI)  portal 
 
 
 
 
 
 
 
 
 
 
(http://adni.loni.ucla.edu). The quality-controlled data consist 
of 146 plasma proteins derived from 58 and 54 healthy controls 
(HCs) at baseline and 12 months later respectively, 136 
individuals with mild cognitive impairment due to AD (MCI) 
at 12 months from baseline, and 108 Alzheimer’s dementia 
(ADD) patients at baseline. The MCI subjects were later 
diagnosed with AD dementia within about 10-year follow-up. 
A list of the 146 proteins are shown in the supplementary 
material. Mild dementia was diagnosed according to NINCDS-
ADRDA criteria for probable ADD. A detailed description of 
the protocol may be found on the ADNI database. The 
demographic information of the subjects is shown in Table I. 
The subjects were age matched, over 70 years old and had about 
16 years of education on average. 
III. METHODS 
A. Data pre-processing 
All study data were standardized as indicated in (1) to ensure 
that proteins with high numeric values relative to others would 
not cause bias in subsequent ML operations. Given a feature 
instance 𝑥, the standardised value 𝑧 is given as, 
  𝑧 =  
𝑥 − 𝜇
𝜎
 (1) 
 Where 𝜇 and 𝜎 are the sample mean and standard deviation of 
the feature distribution, respectively.  
To make optimal use of available data while minimizing 
susceptibility of our approach to overfitting problems, the pre-
processed data were partitioned into two non-overlapping 
datasets; Datasets 1 and 2. Dataset 1 consists of baseline data 
from the ADDs and HCs. All existing methods evaluated in this 
study except [20]   were originally developed based on Dataset 
1. In our approach, Dataset 1 was used to conduct a robust 
feature preselection (a key aspect in ML) and model 
development. 
The resulting models were further evaluated with Dataset 2. 
Dataset 2 consists of month-12 data from MCIs and HCs. It was 
used to assess the performance of the developed models (trained 
on the entirety of Dataset 1) for MCI vs. HC classification. 
Models were trained with only Dataset 1 during model 
development using the entirety of it or its subsamples (in the 
case of cross-validation which is subsequently described). 
B. Replication and evaluation of existing methods 
We replicated the ML models reported in previous studies for 
classification  of  ADD  and  HC subjects  (Dataset 1)  using 10- 
TABLE I 
DEMOGRAPHIC INFORMATION OF SUBJECTS IN STUDY DATA 
Clinical 
groups 
Sample 
size 
Ave. age in 
years (SD) 
Ave. years of 
education (SD) 
% 
Female 
HC 58(54) 75(6) 16(2.8) 48(50) 
MCI 136 75(7) 16(3.0) 45 
ADD 108 75(8) 15(3.2) 46 
SD: standard deviation; HC: healthy control; MCI: mild cognitive impairment; 
ADD: Alzheimer’s dementia 
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Fig. 1. Overall framework for identification of novel putative biomarker panels and model development for early AD detection. K: Different kernels of SVM 
including linear, 2 and 3 -degree polynomials, and radial basis function (RBF), respectively. MSK: Most stable kernel. A stable kernel is one that showed most 
moderate to high performance for most panels. CV: Cross-validation (CV). CP: Candidate panel. A candidate panel is one that meets our performance criteria (SN 
and SP of at least 70%) in the model training and CV step. Sensitivity and specificity have been described elsewhere [28].  
 
fold cross-validation with the average performance of the 
models taken after 10 repetitions. In 10-fold cross-validation, 
the dataset D is randomly split into 10 mutually exclusive 
subsets (the folds) D1, D2, ..., D10 of approximately equal size. 
The classifier is trained and tested 10 times; each time t ∈ {1, 
2, … , 10}, it is trained on D\Dt and tested on Dt [29]. The cross-
validation estimate of the classifier performance is the overall 
performance over all the folds. Repeated cross-validation was 
implemented to ensure a robust estimation of performance [29]. 
The ability of the models to classify MCI and HC was then 
tested with Dataset 2 to assess their potential and hence the 
underlying protein panels to detect early AD. 
C. Novel panel identification and model development 
Fig. 1 shows the methodological framework that we used to 
identify novel blood protein panels and to develop the new ML 
models for early detection of AD. The framework is described 
in detail in the following subsections. Briefly, the framework 
consists of three major procedures which include feature subset 
preselection, protein panel formation, and ML-based model 
development and evaluation. A feature subset preselection 
process was performed to identify protein subsets that may have 
strong discriminatory power between disease subjects (ADD) 
and HCs. A brute force search was applied to the preselected 
feature subset to form several protein panels. Each of the panels 
was then used to develop and cross-validate SVM classifiers of 
different kernels (K) using Dataset 1. Data from ADD subjects 
were used in these initial procedures on the basis that dementia 
subjects are more likely to exhibit the metabolic alterations that 
are associated with the disease. The most stable kernel and 
candidate panels (promising models) trained on Dataset 1 were 
further evaluated for classification of individuals with MCI and 
HCs using Dataset 2. The promising models with best 
performance at this stage were selected as final. The protein 
panels that underlie the selected models are reported as 
potential blood-based non-amyloid biomarker signature of 
early disease.  
1) Feature (protein) subset preselection 
A feature subset preselection procedure was implemented 
with Dataset 1 using correlation-based feature subset selection 
(CFS) method  [30]. The goal of this task was to make an initial 
selection of the most relevant and non-redundant features for 
classification of ADD and HC subjects and consequently 
reduce the dimension of the study data prior to model 
development. Reduction of the dimension of the study data was 
necessary because it would otherwise be computationally 
expensive to implement an exhaustive search to evaluate the 
classification performance of all possible feature subsets with 
ML algorithms. For N-dimensional data (where N is 146 in this 
case) there are 2𝑁 possible feature subsets. 
The CFS approach comes under the broad category of filter-
based feature subset evaluation methods that attempt to remove 
irrelevant and redundant features from data by using 
correlation-based heuristic to determine the worth (merit) of a 
feature subset. This technique has been shown to compare 
favourably with wrapper-based approaches in selecting the best 
feature subsets that achieve high classification accuracy while 
incurring far less computational cost [31]. It is based on a 
heuristic that evaluates the merit of feature subsets following 
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the hypothesis that a good feature subset consists of features 
highly correlated with the class, yet uncorrelated with each 
other. Correlation in this sense refers to the predictability of one 
variable by another. Equation (2) shows the mathematical 
formulation of the CFS heuristics, a concept borrowed from test 
theory [32]. 
 𝑀𝑒𝑟𝑖𝑡 =
𝑘𝑟𝑓𝑐
√𝑘 + 𝑘(𝑘 − 1)𝑟𝑓𝑓
 (2) 
𝑀𝑒𝑟𝑖𝑡 is the heuristic merit of a feature subset consisting of 𝑘 
features, 𝑟𝑓𝑐 is the mean feature-class correlation and 𝑟𝑓𝑓 is the 
mean feature-feature inter-correlation. The parameters, 𝑟𝑓𝑐 and 
𝑟𝑓𝑓 are measures of feature relevance and redundancy, 
respectively, based on the proposition that a feature is relevant 
if it is correlated with the class, otherwise it is irrelevant. 
Redundant features are correlated with one or more other 
features. 
To determine the correlations, continuous features were firstly 
discretized using the discretization method proposed in [33] to 
ensure that all features were uniformly handled. The 
correlations were calculated in terms of modified information 
gain known as symmetrical uncertainty (SU) [34] to cater for 
the bias of information gain in favour of features with more 
values. Values were normalised to the range [0, 1] to ensure that 
they were comparable and had similar effect.  
 SU = 2.0 [
𝑔𝑎𝑖𝑛
𝐻(𝑌) + 𝐻(𝑋)
] (3) 
Where 𝑔𝑎𝑖𝑛 is the information gain [35] for nominal features 𝑋 
and 𝑌, 𝐻(𝑋) and 𝐻(𝑌) are the entropy [36] of 𝑋 and 𝑌, 
respectively. The gain is formulated as, 
 
𝑔𝑎𝑖𝑛 = 𝐻(𝑌) − 𝐻(𝑌|𝑋) 
           = 𝐻(𝑋) − 𝐻(𝑋|𝑌). 
      (4) 
Where, 
 𝐻(𝑌) = − ∑ 𝑝(𝑦) 𝑙𝑜𝑔2 𝑝(𝑦)
𝑦∈𝑌
; (5) 
 𝐻(𝑌|𝑋) = − ∑ 𝑝(𝑥) ∑ 𝑝(𝑦|𝑥) 𝑙𝑜𝑔2 𝑝(𝑦|𝑥)
𝑦∈𝑌𝑥∈𝑋
. (6) 
2) Novel panel formation and SVM-based evaluation 
Firstly, feature panels were formed from the CFS-preselected 
proteins based on a brute force approach. Each panel was then 
evaluated using a wrapper-based method to identify the ML 
algorithm and panels with best performance for classification of 
ADD and HC subjects. Using each panel, several SVM [37] 
classification models were constructed with different kernels 
including linear, 2nd  and 3rd degree polynomials, and radial 
basis function (RBF) using Dataset 1. Average performance of 
each model to classify ADD and HC subjects was obtained 
using a 10-fold cross-validation [29] scheme repeated 10 times. 
Secondly, the performance of most stable models (SVM 
algorithm and feature panels) that met the performance criteria 
of average SN and SP ≥ 70% for classification of ADD and HC 
subjects  was  tested  with  Dataset 2  for  discrimination of  MCI 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Mechanism of SVM classification 
and HC groups. Finally, the models and underlying protein 
panels with best performance in classifying MCI and HC 
groups were selected as putative models and non-amyloid 
biomarker panels for early detection of AD.  
3) Classification with kernelized SVM 
The choice of SVM for the model development task was 
informed by the fact that it is robust even with limited training 
data, and not prone to local extremum [38], as well as our 
previous experience [24]. It is a very powerful tool widely 
applied in similar biomedical applications [39]. SVM classifies 
training instances belonging to either of two classes by fitting a 
separation boundary (hyperplane) between the classes such that 
the margin between the boundary and either class is maximized. 
The class of a new instance is decided depending on which side 
of the hyperplane it lies. Fig. 2 illustrates a 2-class SVM 
classifier.   
Given a 2-class problem with training data consisting of  𝑁 
examples (𝑥1, 𝑦1), (𝑥2, 𝑦2), … , (𝑥𝑁−1, 𝑦𝑁−1), (𝑥𝑁 , 𝑦𝑁), with 
input features 𝑥𝑖 ∈ ℝ
𝑑 and class 𝑦𝑖 ∈ {−1,1}, the goal of SVM 
is to define a hyperplane h(x) that is given by, 
 ℎ(𝑥) = 𝑥𝑇𝑤 + 𝑏 = 0, (7) 
so as to induce a classification decision rule 𝐷(𝑥) that 
maximises the margin 𝑀(= 2𝑚).  
 𝐷(𝑥) = 𝑠𝑖𝑔𝑛(𝑥𝑇𝑤 + 𝑏) (8) 
Finding such a hyperplane involves optimizing 𝑀as,  
 𝑚𝑎𝑥
𝑤,𝑏
𝑀 ≡ 𝑚𝑖𝑛
𝑤,𝑏
1
2
‖𝑤‖2  (9) 
subject to 𝑦𝑖(𝑥𝑖
𝑇𝑤 + 𝑏) ≥ 1,  where 𝑏 is a constant, 𝑑 is the 
dimension of the data, 𝑤 is a vector of unknown length with 𝑑 
dimension pointing from the origin and normal to the margin, 
and 𝑚  is shown to be equal to 
1
‖𝑤‖
. 
The resulting 𝑤 from the optimization in (9) is of the form 
shown in (10), with 𝛼𝑖 being nonzero for instances 𝑖 (known as 
support vectors) where the constraint 𝑦𝑖(𝑤
𝑇𝑥𝑖 + 𝑏) ≥ 1 is met.  
𝑤 = ∑ 𝛼𝑖
𝑁
𝑖=1
𝑦𝑖𝑥𝑖, (10) 
With (10), 𝑏 may be determined from (7), and following from 
(8), the decision rule for a new sample 𝑢 of unknown class may  
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M
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be stated as, 
  𝐷(𝑢) = 𝑠𝑖𝑔𝑛 [𝑢𝑇 (∑ 𝛼𝑖
𝑁
𝑖=1
𝑦𝑖𝑥𝑖) + 𝑏].   (11) 
 Where 𝛼𝑖 are Lagrangian multipliers resulting from the 
optimization of (9). 
When the training data are not linearly separable by a 
hyperplane, SVM may transform the data to new space where 
they become linearly separable by using kernel functions. The 
kernel function simply computes dot products of features in the 
transformed space. One of such kernels is the polynomial kernel 
[40]. For example, given feature vectors 𝑣 and 𝑧, a polynomial 
kernel 𝐾 is formulated as, 
 𝐾(𝑣, 𝑧) = (1 + 𝑣𝑇𝑧)𝑟 .   (12) 
Where r is the degree of the polynomial. 
Thus, for a SVM classifier with a polynomial kernel, the 
solution for the hyperplane (formally determined by 
substituting (10) in (7)) and decision rule for a new sample of 
unknown class are modified as shown in (13) and (14). 
 ℎ̅(𝑥) = ∑ ?̅?𝑖
𝑁
𝑖=1
𝑦𝑖𝐾(𝑥, 𝑥𝑖) + ?̅?   (13) 
 ?̅?(𝑢) = 𝑠𝑖𝑔𝑛[ℎ̅(𝑢)] (14) 
However, because a standard SVM seeks to fit a margin 
separating all positive and negative training instances without 
any error which is not often practicable, a concept known as soft 
margin [37] which permits minimum misclassification error is 
implemented in practical SVM algorithms with a slight 
modification of (9).  
D. Implementation and performance evaluation 
Feature selection using CFS as discussed earlier was 
conducted with attribute selection toolbox in Weka software 
package [41]. All classification tasks were conducted with 
MATLAB and Weka software packages. MATLAB codes are 
available on https://github.com/chimastan/earlydetectionofAD. 
In evaluating the models from previous studies, we used Weka 
where previous studies had used it for model development. 
Training of ML models and validation of performance for ADD 
vs. HC discrimination was based on 10-fold cross-validation 
scheme repeated 10 times. The data (Dataset 1) were randomly 
re-partitioned after each run to ensure that data subsets used for 
training and validation varied from the ones used in the 
preceding run. This way, a more robust average performance is 
obtained. Classification performance metrics of primary 
consideration were measures of SN and SP in accordance with 
international recommendations for clinically usable AD 
biomarkers [42]. A performance threshold of 70% for SN and 
SP was adopted in the model development task. This is on the 
grounds that the diagnostic accuracy of human experts reaches 
77% [43] with sensitivity and specificity reaching 81% and 
70% [5], respectively. Moreover, sensitivity and specificity 
greater than 80% is the target performance for ideal AD 
biomarkers [42]. No class imbalance handling procedure was 
applied to the training dataset (Dataset 1) in model development 
as minority to majority class distribution was 35:65% which is 
acceptable in ML-based classification problems [44, 45]. 
IV. RESULTS 
A. Replication and evaluation of existing models 
We successfully replicated 7 models for classification of 
ADD subjects and HCs. The model proposed by [20] could not 
be replicated because it was originally trained on a dataset not 
available to us. Nevertheless, we constructed a model with 
Dataset 1 based on the ML algorithm and blood protein panel 
proposed by the ([20]) study. Only existing models constructed 
with blood proteins available in our study dataset were 
investigated in this study. Table II shows the average cross-
validated performance of the models repeated over 10 runs for 
classification of ADD and HC subjects. Nearly all the models 
achieved SN, SP, and AUC greater than 80%, 60%, and 0.70, 
respectively. However, when evaluated for possible detection 
of early AD by classifying MCI and HC with Dataset 2, the SN 
values of the models remained moderately high while their SP 
values drastically dropped (with only  one model achieving up 
to 50%). This implies that the models may have undesirably 
high levels of false positives when applied for early disease 
detection.  Consequently, the underlying protein panels may not 
serve as good biomarker signatures of early disease.  
B. Feature subset preselection 
Using our new methodological approach, sixteen proteins 
with a merit (𝑀𝑒𝑟𝑖𝑡) of 0.36 were preselected with the CFS 
technique from the 146 proteins in the original study data. The 
16 proteins are shown in Table III together with their statistical 
significance 𝑃 as calculated with z-test. The z-test was used to 
estimate the statistical significance of the difference between 
the pair of clinical groups being considered together (AD vs. 
HC) and (MCI vs. HC) for the pre-selected features. All except 
a few features were statistically significant (p-value < 0.05) in 
the ADD vs. HC pair (Dataset 1). Most of the features were not 
statistically significant in the MCI vs. HC pair (Dataset 2). This 
may be due to the high imbalance between the samples sizes of 
MCI and the HC in the dataset.  
C. Novel panel formation and SVM-based evaluation 
From the 16 CFS-preselected protein subset, 216 different 
protein panels were formed. Results from wrapper-based 
evaluation of all the panels for classification of ADD and HC 
groups using Dataset 1 showed that models constructed with 2-
degree polynomial kernel had a better and more stable 
performance. Consequently, SVM with 2-degree polynomial 
kernel was selected as the algorithm of choice. Only (10,699) 
2-degree polynomial kernelized SVM models that met our 
performance benchmark (SN and SP ≥ 70%) for ADD and HC 
classification were further evaluated for their potential to detect 
early disease with Dataset 2. Two models constructed with six 
and eight protein panels (A1M, A2M, ApoA2, CD5L, IL3, 
SGOT and A1M, A2M, ApoA2, BNP, BTC, CD5L, IL3, 
SGOT, respectively)  achieved  a  remarkable   cross-validated   
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A1M: alpha-1 microglobulin ; A2M: alpha-2 macroglobulin; ApoA2: apolipoprotein A2; ApoE: apolipoprotein E; BNP: brain natriuretic peptide; BTC: 
betacellulin; CD5L: CD5;  Eot3: Eotaxin 3; IGM: immunoglobulin M; IL3: interleukin 3; MCSF1: monocyte-colony stimulating factor 1; PAPPA: Pregnancy-
Associated Plasma Protein A; PLGF: placenta growth factor; PPP: Pancreatic Polypeptide; PYY – peptide YY; RAGE: receptor for advanced glycosylation 
end; SGOT: serum glutamic oxaloacetic transaminase. 
TABLE IV 
PERFORMANCE OF NOVEL CANDIDATE BLOOD BIOMARKER PANELS FOR EARLY 
DETECTION OF AD 
Panel 
size 
Panel 
ADD vs. HC 
(Dataset 1) 
MCI vs. HC 
(Dataset 2) 
SN SP AUC SN SP AUC 
7 
 
A2M, ApoE, BNP, Eot3, PLGF, 
RAGE, SGOT 
 
88.5 70.4 0.87 80.1 70.4 0.80 
7 
A2M, ApoE, BNP, Eot3, PYY, 
RAGE, SGOT 
88.9 73.8 0.89 77.9 74.1 0.80 
8 
 
A2M, ApoE, Eot3, IGM, MCSF1, 
PYY, RAGE, SGOT 
 
85.3 71.6 0.86 83.8 70.4 0.83 
9 
 
A2M, ApoA2, ApoE, BNP, BTC, 
Eot3, PYY, RAGE, SGOT 
 
85.0 75.0 0.89 80.1 72.2 0.80 
10 
A1M, A2M, ApoE, BNP, BTC, Eot3, 
IGM, MCSF1, PAPPA, SGOT 
88.1 72.9 0.89 83.1 70.4 0.80 
        
 
TABLE III  
CFS-BASED PRESELECTED PROTEINS 
Protein  
 
𝑷 
ADD vs. HC  
(Dataset 1) 
MCI vs. HC  
(Dataset 2) 
 
A1M 
 
2.9E-6 
 
3.3E-1 
A2M 2.5E-3 3.2E-1 
ApoA2 3.2E-8 1.1E-1 
ApoE 1.1E-7 3.8E-4 
BNP 7.7E-7 5.2E-2 
BTC 4.4E-2 2.4E-1 
CD5L 1.0 E-1 8.6E-1 
Eot3 5.5E-5 6.2E-3 
IGM 9.7E-7 3.9E-5 
IL3 8.1E-3 6.9E-15 
MCSF1 4.0E-1 8.4E-2 
PAPPA 7.7E-4 1.6E-1 
PLGF 1.3E-5 3.2E-1 
PYY 2.7E-6 5.9E-1 
RAGE 6.5E-3 6.3E-1 
SGOT 9.2E-6 2.2E-6 
 
TABLE II 
PERFORMANCE OF EXISTING BLOOD BIOMARKER PANELS FOR AD DETECTION 
Study 
 
Panel 
size 
 
Panel 
 
ML model 
 
ADD vs. HC 
(Dataset 1) 
MCI vs. HC 
(Dataset 2) 
SN SP AUC SN SP AUC 
[20] 11 
Adip, B2M, CRP, FABP, FVII, IL18, MCP1, PPP, TLSP, 
TNC, VCAM 
Random forest 85.2 25.9 0.62 81.6 46.3 0.72 
[21] 5 A1M, ApoE, BNP, IL16, SGOT 
Logistic 
regression 
85.2 74.1 0.90 79.0 50.0 0.70 
[22] 
 
8 A1M, ApoA2, ApoE, BNP, Eot3, IGM, PLGF, SGOT 
Random forest 
88.0 72.4 0.87 80.9 46.3 0.69 
5 A1M, ApoA2, ApoE, BNP, SGOT 87.0 62.1 0.83 83.1 38.9 0.67 
13 
ApoA2, ApoE, BNP, Eot3, HBEGF, IGM, IL16, PLGF, 
PYY, SGOT, TNC, TTR, Vit 
92.6 60.3 0.87 85.3 42.6 0.72 
14 
A1M, A2M, ApoA2 ApoE, BNP, BTC, CRP, Eot3, IGM, 
IL16, MPO, PLGF, RAGE, SGOT 
92.6 67.2 0.91 83.1 44.4 0.70 
[23] 6 A1M, A2M, AAT, ApoE, CC3, PPP Naive Bayes 86.1 63.8 0.82 78.3 37.0 0.62 
[24] 5 A1M, A2M, CC3, IGM, TNC SVM 81.1 60.5 0.77 75.7 35.2 0.65 
* Use of apolipoprotein ε4 (APOE4) genotype as covariate in original model proposed in [24] was excluded as distribution of APOE4 status is highly uneven 
in HC group (less than 9% of HCs are positive).  
A1M: alpha-1 microglobulin; A2M: alpha-2 macroglobulin; Adip: adiponectin; ApoA2: apolipoprotein A2; ApoE: apolipoprotein E; B2M: Beta-2-
Microglobulin; BNP: brain natriuretic peptide; BTC: betacellulin; CC3: complement C3; CRP: c-reactive protein; Eot3: Eotaxin 3; FABP: fatty acid binding 
protein; FVII: factor VII; GCSF: granulocyte-colony stimulating factor; HBEGF: heparin-binding EGF-like growth factor; IGM: immunoglobulin M; IL: 
interleukin; MCP1: monocyte chemotactic protein 1 α; MPO: myeloperoxidase; PLGF: placenta growth factor; PPP: Pancreatic Polypeptide; PYY – peptide 
YY; RAGE: receptor for advanced glycosylation end; SGOT: serum glutamic oxaloacetic transaminase; TLSP: t-lymphocyte secreted protein 1.309; TNC: 
tenascin C; TTR: Transthyretin;  VCAM: Vascular Cell Adhesion Molecule-1; Vit: Vitronectin 
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performance (SN of 92% and 93%, SP of 81% and 83%, AUC 
of 0.90 and 0.94 respectively) in classifying ADD and HC 
subjects. This perhaps highlights a possible performance 
benefit of the CFS-based feature preselection technique. 
Nevertheless, the two models performed poorly when evaluated 
for classification of MCI and HC subjects. The implication is 
that an excellent model at later stages of the disease does not 
necessary imply a good disease detection model at the early 
disease stages. This may be attributed to subtle differences in 
the underlying patterns as well as noise in the data among other 
factors, thus highlighting the need for further evaluations. Five 
models constructed with panels shown in Table IV realized best 
performance  for classification of MCI and HC groups. All but 
one of the models detected AD subjects with SN and SP above 
80% and 70% respectively at dementia as well as MCI stage. A 
larger panel formed by combining all five panels in Table IV 
achieved a cross-validated SN, SP, and AUC of 85%, 70%, and 
0.88, respectively in classifying ADD vs. HC.  However, its 
specificity dropped drastically to 52% with 82% SN and 0.73 
AUC when tested for MCI vs. HC classification. The 
introduction of well-known risk factors of AD [46] such as age 
and level of education as covariates to the models did not 
improve performance significantly. APOE4 genotype was not 
used as a covariate to avoid bias since less than 9% of HC group 
have positive status. 
V. DISCUSSION 
In this study, we developed models and identified novel non-
amyloid biomarker panels for early detection of AD following 
a new approach, and demonstrated that existing ML methods 
may not be suitable for early detection. The models and panels 
were selected based on their performance at both the prodromal 
and dementia stages of the disease, thus improving the chance 
that signals about the disease were captured rather than noise 
resulting from individual variations between study participants. 
Ideally, the smaller the size of a panel, the better in terms of 
interpretability and cost of implementation in practical 
applications such as point of care technology. However, 
because our study was exploratory, it was important to flag all 
the panels that achieved reasonably good performance since it 
is unclear which panel or proteins are the most important. 
Gaining such clarification may require further investigation 
such as analysis of protein-protein interaction for the proposed 
panels (see later). We have also shown the performance of the 
larger panel derived by combining all five panels we identified, 
although it has a lower performance relative to the individual 
panels perhaps due to curse of dimensionality. 
Comparing our results (Table IV) with those of existing 
models we investigated (Table II); the best existing model 
identified AD subjects at MCI stage with high sensitivity and 
fairly good specificity (79% SN and 50% SP) while our model 
with the least panel size achieved a better performance with 
80% SN and 70% SP. At dementia stage, our proposed models 
achieved a performance that is comparable to the best model 
from the investigated studies. 
Comparing our results with  the  three recent relevant studies  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(see Table V), we note that the panels identified in [25] and [26] 
classified ADD and HC with high performance, but the markers 
were reported by the authors to be poor at distinguishing 
between MCI and HC. Furthermore, while study [27] achieved 
high AUC of 0.88 with XGBoost model for classification of 
ADD and HC, the model’s performance has not been evaluated 
for disease detection at MCI stage. Due to unavailability of 
biomarkers used in the study in our study data, the performance 
of the models for MCI and HC classification was not 
investigated in this study. In contrast to the recent studies, our 
models achieved high performance for disease detection at 
ADD stage (with one of the models shown in the table realising 
best AUC, with high sensitivity and specificity) as well as the 
MCI stage. 
Our proposed panels differ significantly from those of 
existing methods. This may be due to significant differences in 
the approaches including feature preselection and evaluation 
modalities which were deliberately applied in this study. We are 
not aware of the use of CFS for feature preselection in previous 
studies. We have provided details of the ML algorithm used 
including the kernel type and order as well as their selection 
process to ensure transparency of approach and reproducibility. 
In future, the study will be validated in independent cohorts and 
extended to preclinical stages of the disease.   
It is noteworthy that no existing AD model based on non-
amyloid proteins has hitherto been evaluated for early disease 
detection using ADNI data. 
Regarding the proteins evaluated in this study, besides 
PAPPA, which is rather highly associated with depressive 
symptoms in older adults [47] other proteins preselected by 
CFS have been previously identified in several studies [16-24] 
to have classification value in discriminating between ADD and 
HC groups. From the five selected panels shown in Table IV, 
six proteins (i.e., A2M, ApoE, BNP, Eot3, RAGE, and SGOT) 
appear as most prominent, featuring in nearly all the panels. A 
combination of the six proteins therefore seem to play a 
significant role in the discrimination of disease (prodromal and 
dementia) subjects and healthy controls. The panel classified 
both groups with sensitivity and specificity > 80% and 65%, 
respectively and AUC of at least 0.80.  Several of these proteins 
are found in nearly all the previously reported models 
TABLE V 
COMPARISON OF OUR RESULTS WITH RECENT RELEVANT STUDIES 
Study 
 
ML model 
 
ADD vs. HC MCI vs. HC 
SN SP AUC SN SP AUC 
[25] 
Logistic 
regression 
84.0 70.0 0.79 poor 
[26] 
Random 
forest 
90.0 67.0 0.77 poor 
 XGBoost - - 0.88 - - - 
[27] 
Random 
forest 
- - 0.85 - - - 
 Deep learning - - 0.85 - - - 
Current 
study 
SVM 85.0 75.0 0.89 80.1 72.2 0.80 
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investigated in this study. Studies show that blood plasma levels 
of A2M are linked to mechanisms related to blood-brain barrier 
damage and neuronal injury as well as hippocampus 
metabolism in early AD [15, 48]. ApoE in blood is speculated 
as a dementia risk marker in preclinical AD [49]. BNP levels in 
plasma is associated with decline in cognitive function [50]. 
Plasma levels of RAGE are altered in AD [51]. RAGE has been 
reported to play a critical role in AD and considered as a 
potential therapeutic target [52]. SGOT is a biomarker of 
peripheral inflammation and an essential metabolic enzyme. It 
is often used as a clinical measure of liver function [53]. 
Interestingly, a recent finding has implicated liver function as a 
potential significant confounding factor in the onset of AD 
(https://www.alz.org/aaic/releases_2018/AAIC18-Tues-gut-
liver-brain-axis.asp). 
However, this study has several limitations including the 
following:  
Sample size and ML method: In this work, the sample size of 
study data was small. This is because of the limited availability 
of relevant data due in part to the high cost of collection of such 
specialized data. As a result of the limited dataset, latest ML 
methods such as deep learning (DL) were not explored in this 
study owing to their requirement for large datasets. As more 
data become available, we shall explore DL methods such as 
convolutional and recurrent neural networks [54, 55].  
Nevertheless, conventional machine learning methods are still 
attractive in this domain given their relative simplicity, cheaper 
cost, and usefulness for data modeling [56]. However, despite 
the high classification performance achieved by the traditional 
ML approach we applied, there are other methods such as 
ensemble learning [57] that have the potential to improve 
performance and therefore may be applied in future study. 
Demographics: Another limitation is that the study data only 
consist of older and educated subjects. Thus, our findings may 
not generalise well to other cohorts such as less educated 
individuals given that level of education is a well-known risk 
factor for AD.  
Feature selection method: Notwithstanding the usefulness of 
CFS feature preselection technique applied for dimensionality 
reduction and mitigation of model overfitting, some important 
markers with strong biological links to AD may have been 
eliminated as the process was blind to prior knowledge.  
Protein-protein interaction analysis: In this study, aspects such 
as protein-protein interaction were not investigated as these 
were beyond the scope of the study. Potentially, analysis of the 
interactions between proteins in the identified panels may 
facilitate understanding of their joint role in AD process and 
clarify which panel(s) are more clinically relevant. 
In view of the limitations above, there is a need to conduct 
additional follow-up studies and validation of our findings in 
large and independent cohorts considering that validation of 
findings is an important step for clinical acceptance and 
translation into clinical practice.  
Besides proteomics-based biomarkers, there are also other 
nonamyloid-based blood biomarkers such as mRNA [58, 59] 
and autoantibodies [60] where progress is being made in AD 
detection and improving understanding of disease. For instance 
in [58], three mRNA biomarkers that suggest important 
dysregulated pathways in AD pathogenesis have been 
identified. Therefore, future studies should consider the 
exploitation of a range of blood-based biomarkers including 
proteomics and mRNA. This may lead to a more accurate panel 
of blood biomarkers to detect AD and improve the 
understanding of its aetiology. 
  Overall, the results from this study suggest that it may be 
feasible to detect early AD using a profile of non-amyloid 
proteins in blood associated with the metabolic processes that 
accompany or precede the disease. Because the proteins are 
non-amyloid based, they have the potential to detect the disease 
even before amyloid pathology develops. It may be possible to 
develop new understanding of the disease through further 
studies of these proteins and their protein-protein interactions 
in the disease pathogenesis. Such understanding may aid the 
development of new interventions in response to current failure 
of clinical trials targeting amyloid clearance. The main 
contributions of this study include the potential biomarker 
signatures identified and the methodological approach adopted 
in the search for these signatures in an effort to bridge an 
important study gap of early detection of AD with proteomic-
based non-amyloid blood biomarkers.  
VI. CONCLUSION 
We have developed potential models and identified five novel 
candidate non-amyloid biomarker panels for early detection of 
AD utilizing a new approach. The developed models based on 
these panels classified prodromal AD as well as AD dementia 
and normal controls with sensitivity above 80%, specificity 
higher than 70%, and AUC of at least 0.80. A combination of 
A2M, ApoE, BNP, Eot3, RAGE and SGOT were identified as 
key protein profiles with significant contribution to the 
classifications performance. The results suggest that it may be 
feasible to detect early AD using a profile of non-amyloid 
proteins that identify the metabolic processes that accompany 
or precede the disease. It may be therefore possible to detect the 
disease with the proteins before amyloid pathology (the earliest 
signature current diagnostic biomarkers can detect) develops 
since they are not amyloid-based. This may aid identification of 
individuals at the earliest stages of AD who may benefit from 
early interventions. Furthermore, new insights about the disease 
may be gained from understanding the interactions between the 
proteins in disease subjects. Such enhanced understanding may 
contribute to the improvement of interventions in clinical trials. 
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